RLAY vs RXRX
RLAY and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | RLAYRelay Therapeutics, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $3.81B | — |
| P/S | 248.4x | — |
| Revenue growth (YoY) | 53.4% | 26.9% |
| Earnings growth (YoY) | 18.1% | -39.1% |
| EBIT margin | -1971.6% | -867.9% |
| ROE | -43.1% | -62.9% |
| ROIC | — | -174.7% |
| 1y total return | +445.3% | -46.7% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: RLAY vs RXRX
| 지표 | RLAY | RXRX |
|---|---|---|
| 최종 가치 | $6.1K | $941 |
| 총수익률 | -38.9% | -90.6% |
| CAGR | -9.0% | -36.2% |
| 변동성 | 77.4% | 93.2% |
| 샤프 | 0.21 | -0.08 |
| 소르티노 | 0.32 | -0.13 |
| 최대 낙폭 | -94.7% | -93.1% |
공통 거래일 1319일 기준, 2021-04-16 → 2026-07-17 · 무위험수익률 3.85% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)